Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium dobesilate in diabetic nephropathy and chronic venous insufficiency
ISRCTN19391899Phase 4Completed
- Sponsor
- OM Pharma
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of calcium dobesilate in diabetic glomerulosclerosis and venous stasis, sponsored by OM Pharma. Primary endpoint: Urinary albumin excretion at day 120. Started Mar 2024; status: completed.
02
Drugs
calcium dobesilate
03
Conditions
diabetic glomerulosclerosisvenous stasis
Beyond the preview
Go deeper on ISRCTN19391899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19391899.